Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 versus recombinant human thrombopoietin for cancer therapy-induced thrombocytopenia
ChiCTR2600135397Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of romiplostim and recombinant human thrombopoietin in Thrombocytopenia (2 arms), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Platelet count. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
romiplostimrecombinant human thrombopoietin
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on ChiCTR2600135397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135397.